Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
McKinsey
US Army
Julphar
Cerilliant
Queensland Health
Chinese Patent Office
Mallinckrodt
Colorcon

Generated: October 19, 2017

DrugPatentWatch Database Preview

OXTELLAR XR Drug Profile

« Back to Dashboard

Which patents cover Oxtellar Xr, and what generic Oxtellar Xr alternatives are available?

Oxtellar Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has fourteen patent family members in ten countries.

The generic ingredient in OXTELLAR XR is oxcarbazepine. There are nineteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.

Summary for Tradename: OXTELLAR XR

US Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list59
Clinical Trials: see list1
Patent Applications: see list2,858
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OXTELLAR XR at DailyMed

Pharmacology for Tradename: OXTELLAR XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-001Oct 19, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-003Oct 19, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-001Oct 19, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-001Oct 19, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-002Oct 19, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-003Oct 19, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-002Oct 19, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-003Oct 19, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-003Oct 19, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Supernus Pharms
OXTELLAR XR
oxcarbazepine
TABLET, EXTENDED RELEASE;ORAL202810-002Oct 19, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for OXTELLAR XR

Drugname Dosage Strength RLD Submissiondate
oxcarbazepineExtended-release Tablets150 mg and 300 mgOxtellar XR4/12/2013

Non-Orange Book Patents for Tradename: OXTELLAR XR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,017,149Modified release preparations containing oxcarbazepine and derivatives thereof► Subscribe
9,119,792Modified release preparations containing oxcarbazepine and derivatives thereof► Subscribe
8,211,464Modified release preparations containing oxcarbazepine and derivatives thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OXTELLAR XR

Country Document Number Estimated Expiration
Mexico2008013675► Subscribe
European Patent Office2026815► Subscribe
Spain2396051► Subscribe
Canada2597740► Subscribe
Australia2007242984► Subscribe
Japan2009535351► Subscribe
World Intellectual Property Organization (WIPO)2007127630► Subscribe
China101489560► Subscribe
Japan2013079267► Subscribe
European Patent Office2359830► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Cantor Fitzgerald
Johnson and Johnson
Boehringer Ingelheim
UBS
Deloitte
Daiichi Sankyo
Merck
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot